CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 100 filers reported holding CUE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $713,426 | +259.0% | 346,212 | +513.6% | 0.15% | +234.1% |
| Q2 2023 | $198,722 | +23.6% | 56,420 | 0.0% | 0.04% | -27.9% |
| Q4 2022 | $160,798 | -92.0% | 56,420 | -93.3% | 0.06% | -87.7% |
| Q3 2022 | $2,020,000 | +12.0% | 848,048 | +15.2% | 0.50% | +25.6% |
| Q2 2022 | $1,803,000 | -57.7% | 736,212 | -15.7% | 0.39% | -52.5% |
| Q1 2022 | $4,261,000 | -3.5% | 873,021 | +143.1% | 0.83% | +8.6% |
| Q4 2021 | $4,416,000 | +7.6% | 359,113 | +17.5% | 0.76% | +2.3% |
| Q3 2021 | $4,103,000 | +48.0% | 305,732 | +23.3% | 0.75% | +38.6% |
| Q2 2021 | $2,772,000 | -36.8% | 247,924 | -29.7% | 0.54% | -41.9% |
| Q1 2021 | $4,385,000 | +79.1% | 352,534 | +82.1% | 0.93% | +66.4% |
| Q4 2020 | $2,449,000 | +5.9% | 193,591 | +35.9% | 0.56% | -11.3% |
| Q3 2020 | $2,312,000 | +103.2% | 142,430 | +104.2% | 0.63% | +143.4% |
| Q4 2019 | $1,138,000 | – | 69,750 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,510,282 | $7,370,000 | 4.76% |
| SANDERS MORRIS HARRIS LLC | 873,021 | $4,261,000 | 0.83% |
| P.A.W. CAPITAL CORP | 150,000 | $732,000 | 0.76% |
| Nantahala Capital Management | 2,244,359 | $10,952,000 | 0.48% |
| Bleichroeder LP | 552,000 | $2,694,000 | 0.48% |
| APOGEM CAPITAL LLC | 111,259 | $543,000 | 0.37% |
| Slate Path Capital LP | 1,483,619 | $7,240,000 | 0.37% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $2,335,000 | 0.20% |
| CARLSON CAPITAL L P | 405,000 | $1,976,000 | 0.14% |
| Bridgefront Capital, LLC | 19,968 | $97,000 | 0.12% |